CorNeat Vision Overview
CorNeat Vision is a medical device company developing and marketing novel, permanent and tissue-integrating implants. Our platform material technology, CorNeat EverMatrix™, overcomes the main issue with implants and implantables – the foreign body response they trigger. The EverMatrix™ seamlessly and permanently embeds with live tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants. The EverMatrix™ is set to displace harvested and processed human and animal tissues, including scaffolds and extra cellular matrices, used in a variety of surgical procedures across diversified fields of medicine.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- CorNeat Vision, an innovative ophthalmic medical device company, has announced a groundbreaking clinical achievement: the restoration of...
CorNeat Vision, an ophthalmic medical device company, has achieved a significant milestone in its RESEE clinical trial, reaching 50% enrollment. The trial focuses on the CorNeat KPro, an artificial cornea that has successfully restored perfect vision in a patient blinded by corneal scarring from Shingles. This achievement is notable as the patient was not a candidate for traditional corneal transplantation. The CorNeat KPro integrates with the eye wall, eliminating the need for donor tissue and providing long-term stability. The trial aims for FDA 510(k) clearance and CE Marking, with expansion plans to include US clinical centers by 2026. The project is supported by the European Innovation Council and a U.S. Army Project Award.
Product StageFDA approved/pending approval
growth-positive
FDA Approves Israeli Non-Degradable Synthetic Eye Tissue
The American Food & Drug Administration (FDA) has approved an Israeli-made synthetic tissue substitute for the eye developed by Israeli startup CorNeat Vision. The product, EverPatch, is the world’s first non-degradable synthetic tissue for ophthalmic surgery. It is made of a polymer that stimulates the cells to accept it and incorporate it into the eye tissue. The EverPatch was designed to replace the use of donor tissue, which poses the risk of disease transmission. It will be launched initially in the leading ophthalmic centers in the US in the coming months, and expand nationwide later in the year.
CustomersExpand
growth-positive
CorNeat Vision raises $4 million from Israeli-Chinese GIBF fund
Israel-based medtech startup, CorNeat Vision, has raised $4 million from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF). The funds will be invested in CorNeats Chinese subsidiary in Guangzhou, with the aim to expand the companys activities in the Chinese market. This includes conducting clinical trials, setting up a manufacturing facility, and marketing the companys first two products. CorNeat Vision, founded in 2015, develops a synthetic cornea that operates by inserting artificial optics under the membrane that covers the white of the eyes.
InvestmentExpand
growth-positive
https://www.jpost.com/opinion/hillels-tech-corner-corneat-vision-helping-blind-people-see-again-657891
CorNeat Vision, an Israeli company, has developed a technology that has helped a blind man see again. The company was founded in 2015 and focuses on clinical-stage, biomimetic implant technology. They have invented an artificial cornea and a synthetic non-degradable patch that are currently in clinical trials. They have also developed a glaucoma drainage device and a product for gingival recession that are in advanced animal testing. The company has raised over $12 million from private investors and a Swiss hedge fund. They plan to continue investing in low-medium income countries and offer their solutions there.
InvestmentExpand
growth-positive
Jamal can see again, thanks to new synthetic cornea
CorNeat Vision, a company based in Raanana, has successfully implanted its KPro artificial cornea into a patient, restoring his vision. The patient, Jamal Furani, had lost his vision due to corneal disease and previous donor transplants had failed. The successful surgery took place on January 3rd. CorNeat Visions cofounder, CEO & VP R&D, Almog Aley-Raz, stated that this is the first step in a multinational clinical trial, with the aim of attaining CE Mark, FDA clearance and China NMPA approval. The company plans to initiate a second study later this year.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.77M |
| Last funding | $2.5M |
| Stage | B |
| Rounds | 7 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.corneat.com/ |
Locations
4 HaSheizaf Street, Ra'anana, Israel
Photos & Videos
4 item(s)